Development of a rebamipide solid dispersion system with improved dissolution and oral bioavailability
- 624 Downloads
The purpose of this study was to improve the gastric solubility and bioavailability of rebamipide (RBM) by preparing the RBM solid dispersion tablet (RBM-SDT) from solid dispersion powder prepared by spray-drying technique. For preparation of rebamipide solid dispersions (RBM-SDs), solubility study was performed in various hydrophilic carriers and alkalizers, among which sodium alginate and sodium carbonate were selected as the hydrophilic polymer and alkalizer, respectively. Different combinations of drug–polymer–alkalizer were dissolved in aqueous solution and spray-dried in order to obtain solid dispersions. Noticeable improvement in aqueous solubility (approximately 200 times) and in vitro dissolution rate was observed by RBM-SDs, compared to RBM powder. The optimized formulation of RBM-SD powder consisted of RBM powder/sodium alginate/sodium carbonate at the weight ratio of 1/2/2. The transformation of crystalline RBM to amorphous RBM-SD powder was clearly demonstrated by powder X-ray diffraction, differential scanning calorimetry (DSC) and scanning electron microscopy. The optimized RBM-SD was formulated in tablet dosage form, containing approximately 2 % sodium lauryl sulphate and poloxamer F68 as wetting agents. The RBM-SDT exhibited enhanced dissolution in hydrochloric acid buffer (pH 1.2) and distilled water. Moreover, pharmacokinetic study in rats showed higher AUC and Cmax for RBM-SDT than those for RBM powder and commercial product. Thus, the developed RBM-SDT formulation can be more efficacious for improving oral bioavailability of RBM.
KeywordsRebamipide Solubility Solid dispersion Spray-drying Bioavailability
This study was supported by a grant from the Medical Cluster R&D Support Project of Daegu Gyeongbuk Medical Innovation Foundation, Republic of Korea (2013) (No. HT13C0011).
- Arakawa, T., K. Kobayashi, T. Yoshikawa, and A. Tarnawski. 1998. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Digestive Diseases and Sciences 43: 5–13.Google Scholar
- Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed. New York: Marcel-Dekker.Google Scholar
- Li, S., C. Pollock-Dove, L.C. Dong, J. Chen, A.A. Creasey, and W.G. Dai. 2012b. Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: A case study. Molecular Pharmaceutics 9: 1100–1108.PubMedGoogle Scholar
- Miyake, M., Y. Oka, T. Minami, H. Toguchi, M. Odomi, K. Ogawara, K. Higaki, and T. Kimura. 2003. Combinatorial use of sodium laurate with taurine or l-glutamine enhances colonic absorption of rebamipide, poorly absorbable antiulcer drug, without any serious histopathological mucosal damages. Journal of Pharmaceutical Sciences 92: 911–921.CrossRefPubMedGoogle Scholar
- Newa, M., K.H. Bhandari, D.X. Li, T.H. Kwon, J.A. Kim, B.K. Yoo, J.S. Woo, W.S. Lyoo, C.S. Yong, and H.G. Choi. 2007. Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. International Journal of Pharmaceutics 343: 228–237.CrossRefPubMedGoogle Scholar
- Newa, M., K.H. Bhandari, D.X. Li, J.O. Kim, D.S. Yoo, J.A. Kim, B.K. Yoo, J.S. Woo, W.S. Lyoo, C.S. Yong, and H.G. Choi. 2008. Preparation and evaluation of immediate release ibuprofen solid dispersions using polyethylene glycol 4000. Biological and Pharmaceutical Bulletin 31: 939–945.CrossRefPubMedGoogle Scholar
- Rho, J.I. 2003. A new rebamipide lysinate, rebamipide argininate and pharmaceutical preparation containing the same as active substance. Korea Patent 10 2003 0035382.Google Scholar
- Society of Toxicology (SOT). 2008. Guiding Principles in the Use of Animals in Toxicology. www.toxicology.org/AI/FA/guidingprinciples.pdf. Accessed 20 Dec 2013.
- Tran, H.T.T., J.B. Park, K.H. Hong, H.G. Choi, H.K. Han, J. Lee, K.T. Oh, and B.J. Lee. 2011. Preparation and characterization of pH-independent sustained release tablet containing solid dispersion granules of a poorly water-soluble drug. International Journal of Pharmaceutics 415: 83–88.CrossRefPubMedGoogle Scholar
- Tran, T.H., B.K. Poudel, N. Marasini, S.C. Chi, H.G. Choi, C.S. Yong, and J.O. Kim. 2013. Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray drying technique without an organic solvent. International Journal of Pharmaceutics 443: 50–57.CrossRefPubMedGoogle Scholar
- US Food and Drug Administration. 2009. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf. Accessed 15 Jan 2014.
- Visser, M.R., L. Baert, G.V. Klooster, L. Schueller, M. Geldof, I. Vanwelkenhuysen, H.D. Kock, S.D. Meyer, H.W. Frijlink, J. Rosier, and W.L.J. Hinrichs. 2010. Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240. European Journal of Pharmaceutics and Biopharmaceutics 74: 233–238.CrossRefPubMedGoogle Scholar
- Yong, C.S., D.X. Li, D.H. Oh, J.A. Kim, B.K. Yoo, J.S. Woo, J.D. Rhee, and H.G. Choi. 2005. Retarded dissolution of ibuprofen in gelatin microcapsule by cross-linking with glutaraldehyde. Archives of Pharmacal Research 29: 431–534.Google Scholar